Energy from E. coli

From left: Jay Keasling with Francesco Pingitore and Chris Petzold. Credit: Courtesy of Lawrence Berkeley Nat'l Lab - Roy Kaltschmidt, photographer" />From left: Jay Keasling with Francesco Pingitore and Chris Petzold. Credit: Courtesy of Lawrence Berkeley Nat'l Lab - Roy Kaltschmidt, photographer Jay Keasling watches as 700 billion Escherichia coli swish around inside a benchtop bioreactor in the brand-spanking new

Written byBrendan Borrell
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Jay Keasling watches as 700 billion Escherichia coli swish around inside a benchtop bioreactor in the brand-spanking new fermentation room of the Joint BioEnergy Institute in Emeryville, Calif. Seven copper pipes line the wall with a ready supply of nitrogen, oxygen, water, and other essentials, while an automated controller-looking like a souped-up frozen yogurt machine-regulates the temperature, pH, and oxygenation of the cloudy solution brewing within this one liter tank. This isn't just any E. coli multiplying inside, Keasling says proudly, "This is a strain we engineered and now it's producing biodiesel."

If anyone can marshal in the new era of alternative energy, it may well be Keasling, a bioengineer at the University of California, Berkeley, and the CEO of JBEI, which is a US Department of Energy-sponsored partnership between three California universities and three national laboratories. In the last five years, Keasling has coaxed yeast to synthesize the antimalarial ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies